Skip to Content
Merck
All Photos(1)

Key Documents

SML1710

Sigma-Aldrich

Talniflumate

≥98% (HPLC)

Synonym(s):

2-[[3-(Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid 1,3-dihydro-3-oxo-1-isobenzofuranyl ester

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C21H13F3N2O4
CAS Number:
66898-62-2
Molecular Weight:
414.33
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 5 mg/mL, clear (warmed)

storage temp.

room temp

InChI

1S/C21H13F3N2O4/c22-21(23,24)12-5-3-6-13(11-12)26-17-16(9-4-10-25-17)19(28)30-20-15-8-2-1-7-14(15)18(27)29-20/h1-11,20H,(H,25,26)

InChI key

ANMLJLFWUCQGKZ-UHFFFAOYSA-N

Biochem/physiol Actions

Talniflumate is a phthalidyl ester of niflumic acid. It acts as an anti-inflammatory molecule and a mucoregulator. Talniflumate is used as a potent therapeutic for cystic fibrosis, chronic obstructive pulmonary disease and asthma. Talniflumate also inhibits the calcium-activated chloride channel hCLCA function, which is involved in mucus overproduction.
Talniflumate is an orally available, potent and selective inhibitor of core mucin-synthesizing enzyme GCNT3 (core 2 b-1,6 N-acetylglucosaminyltransferase). Talniflumate decreases GCNT3 expression and production of mucins in vivo and in vitro. Talniflumate improves responsiveness of pancreatic tumors to gefitinib. Talniflumate is a potent calcium-activated chloride channel (CaCC) blocker.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Talniflumate (Genaera).
Knight D.
Current Opinion in Investigational Drugs, 5(5), 557-562 (2004)
Nancy M Walker et al.
The Journal of pharmacology and experimental therapeutics, 317(1), 275-283 (2005-12-16)
Intestinal disease in cystic fibrosis (CF) mice closely mirrors aspects of obstructive syndromes in CF patients. The pathogenesis involves accumulation of mucoid debris in the crypts that fuse with intestinal content to form obstructing mucofeculant impactions. Treatment involves modalities that

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service